Diplomat Pharmacy Inc. (DPLO)

25.90
1.30 4.70
NYSE : Health Services
Prev Close 27.17
Open 26.99
Day Low/High 25.66 / 27.14
52 Wk Low/High 14.23 / 27.78
Volume 266.71K
Avg Volume 802.90K
Exchange NYSE
Shares Outstanding 74.13M
Market Cap 2.00B
EPS 0.20
P/E Ratio 179.87
Div & Yield N.A. (N.A)

Latest News

Diplomat Pharmacy In Final Stages Of CEO Search Process

Jeff Park Resigns Voluntarily as Interim CEO

Diplomat Launches CastiaRx, Industry-Leading Specialty Benefit Manager

The nation's largest independent provider of specialty pharmacy services unites benefit-management companies to form specialty-focused CastiaRx.

Healthcare Stocks Trade Mixed on Cigna's Massive $67 Billion Express Scripts Bid

Healthcare Stocks Trade Mixed on Cigna's Massive $67 Billion Express Scripts Bid

As further consolidation in the industry comes back into focus, stocks are teetering.

Diplomat Managing Rising Drug Costs To Support Patients

Diplomat Managing Rising Drug Costs To Support Patients

The nation's largest independent provider of specialty pharmacy services outlines initiatives to control rising drug costs.

Short Interest Expands By 18.8% For DPLO

Short Interest Expands By 18.8% For DPLO

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,278,745 share increase in total short interest for Diplomat Pharmacy Inc , to 8,070,336, an increase of 18.83% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

ThriveRx Wins ASPEN Clinical Nutrition Team Of Distinction Award

ThriveRx Wins ASPEN Clinical Nutrition Team Of Distinction Award

ThriveRx, a division of Diplomat Specialty Infusion Group, has been recognized since 2013 for excellence in interdisciplinary clinical nutrition practice.

Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®

Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®

The nation's largest independent specialty pharmacy is dispensing CABOMETYX® (cabozantinib) tablets, now with an expanded indication to include first-line therapy for patients with advanced renal cell carcinoma

Diplomat Initiates CEO Transition; Reaffirms 2017 Guidance And Provides Preliminary 2018 Outlook

Diplomat Initiates CEO Transition; Reaffirms 2017 Guidance And Provides Preliminary 2018 Outlook

Appoints Jeff Park as Interim Chief Executive Officer Following Retirement of Phil Hagerman

Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook

Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook

The nation's largest independent provider of specialty pharmacy services announces reaffirmed guidance for 2017 and preliminary 2018 projections.

Diplomat Completes Acquisition Of LDI Integrated Pharmacy Services, Secures New Credit Facilities

Diplomat Completes Acquisition Of LDI Integrated Pharmacy Services, Secures New Credit Facilities

The nation's largest independent provider of specialty pharmacy services closes deal to acquire pharmacy benefit manager and announces new $800 million senior secured credit facilities.

Masco, Diplomat Pharmacy, Vail Resorts: 'Mad Money' Lightning Round

Masco, Diplomat Pharmacy, Vail Resorts: 'Mad Money' Lightning Round

Jim Cramer highlights Automatic Data Processing, Masco, Diplomat Pharmacy, Vail Resorts, and Boston Scientific.

What it Takes to Power This Bull: Cramer's 'Mad Money' Recap (Thursday 11/30/17)

What it Takes to Power This Bull: Cramer's 'Mad Money' Recap (Thursday 11/30/17)

Lose the cynicism or you might miss the move. Jim Cramer outlines the reasons for these gains and why investors need to watch them.

First Week of DPLO January 2018 Options Trading

First Week of DPLO January 2018 Options Trading

Investors in Diplomat Pharmacy Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DPLO options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

DPLO: Insiders vs. Shorts

DPLO: Insiders vs. Shorts

The most recent short interest data was recently released for the 10/31/2017 settlement date, and Diplomat Pharmacy Inc is one of the most shorted stocks of the Russell 3000, based on 19.04 "days to cover" versus the median component at 5.18. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

DPLO Crosses Above Average Analyst Target

DPLO Crosses Above Average Analyst Target

In recent trading, shares of Diplomat Pharmacy Inc have crossed above the average analyst 12-month target price of $19.25, changing hands for $20.56/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Amazon's Possible Move Into Pharmacies Has Everyone in Health Industry Talking

Amazon's Possible Move Into Pharmacies Has Everyone in Health Industry Talking

The e-commerce giant reportedly plans to make a decision before Thanksgiving on whether to enter the prescription drug market. Observers weigh in on how its potential entry could impact the landscape.

DPLO Crosses Above Average Analyst Target

DPLO Crosses Above Average Analyst Target

In recent trading, shares of Diplomat Pharmacy Inc have crossed above the average analyst 12-month target price of $17.58, changing hands for $18.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DPLO, ERJ, HOLI, OSIS Downgrades: ABG, AMS, BP, BWINB, CYBR, ISSC, LYTS, MXL, NAT, NNA, NSU, TUP Initiations: ESDI, NH Read on to get TheStreet Quant Ratings' detailed report:

DIPLOMAT PHARMACY (DPLO) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Diplomat Pharmacy, Inc. For Potential Securities Violations And Breaches Of Fiduciary Duty

DIPLOMAT PHARMACY (DPLO) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Diplomat Pharmacy, Inc. For Potential Securities Violations And Breaches Of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violation claims and breach of fiduciary duty claims...

Diplomat Pharmacy Reaches Analyst Target Price

In recent trading, shares of Diplomat Pharmacy Inc have crossed above the average analyst 12-month target price of $17.93, changing hands for $18.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

5 Earnings Short-Squeeze Plays: Snap, NVIDIA & More

5 Earnings Short-Squeeze Plays: Snap, NVIDIA & More

These heavily shorted stocks could squeeze the short-sellers if they report bullish earnings this week.

TheStreet Quant Rating: C (Hold)